SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jenna who wrote (21399)1/7/1999 6:18:00 AM
From: kha vu  Read Replies (2) of 120523
 
WSJ: Heard On The Street 01/06 -- Monsato.
MTC got FDA approval of Celebrex as pain killer for arthritis applications whereas MTC and investors have been expected this drug
to be approved as nonsteroidal antiflammatory drugs,NSAIDs, to treat any type of pain. FDA also requires Celebrex to include
gastrointestinal ulcer warnings to the label. The silver lining for MTC is the FDA approval made Celebrex the first in the new class of pain killer called Cox-2 inhibitors. Safety in this new class can rack up the sale to $1 billion range as of next year.

But investors also learn that Merk, MRK, is expected to launch its Cox-2 inhibitor: Vioxx in about 2 to 3 months. FDA will approve
MRK applications as a broader pain medication. Shares of MRK has been up since then.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News